IP Library Granted Patent US 6,984,650
Granted Patent B2
US 6,984,650 · App. 10/637,190 · Granted Jan 10, 2006

Use of FXR ligands

Assignee: Smithkline Beecham Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,984,650
App. No.
10/637,190
Granted
Jan 10, 2006
Kind
B2
Abstract

The present invention includes nuclear receptor heterodimer and nuclear receptor-coactivator peptide assays for identifying ligands for nuclear receptors, utilizing scintillation proximity and fluorescence resonance energy transfer (FRET), and methods of using identified ligands.

Claims (3)

1. A method of lowering serum triglycerides in a mammal comprising administering to a mammal in need thereof an effeetive serum triglyceride lowering amount of a nonsteroidal agonist for Farnesoid X Receptor of the following formula:

wherein X 1 is CH, N; X 2 is O or NH; R and R 1 are independently H, lower alkyl, halogen, or CF 3 ; R 2 is lower alkyl; R 3 and R 4 are independently H, lower alkyl, halogen, CF 3 , OH, O-alkyl, or O-polyhaloalkyl.

2. The method of claim 1 , wherein said FXR agonist has the following formula:

Continuity (3)
Continuation 0986839700
Provisional Application 6013509700 · Dec 23, 1998
Related Publication 20040048316A1 · Mar 11, 2004